Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Morgan Rl Lichtenstein"'
Autor:
Morgan RL Lichtenstein, Laura Levit, Caroline Schenkel, Margaret Kelsey Kirkwood, Michael J. Kelley, Josh Mailman, Allison Magnuson, Daniel P. Mirda, Divya Natesan, Lola A. Fashoyin-Aje, Dawn L. Hershman
Publikováno v:
Journal of Clinical Oncology. 40:385-385
385 Background: Since the onset of COVID-19, oncology practices across the U.S. have integrated telemedicine (TM) and remote patient monitoring (RPM) into routine care and clinical trials. However, the extent of provider experience and comfort with T
Autor:
Morgan RL Lichtenstein, Erik Harden, Nicole Collins, Khadija Faheem, Peter Campbell, Khilna Patel, Michelle K. Nguyen, Rachel Abramova, Melissa Parsons Beauchemin, Dawn L. Hershman
Publikováno v:
Journal of Clinical Oncology. 40:94-94
94 Background: During the COVID-19 pandemic, remote cancer care, and video communication in particular, has become increasingly common in the context of routine visits and clinical trials. Though this medium has the potential to augment patient-provi
Autor:
Beverly Moy, Emily Gorton, Ryan D. Nipp, Hang Lee, Elyse R. Park, Morgan Rl Lichtenstein, Bruce A. Chabner, Salome Kuchukhidze
Publikováno v:
The Oncologist
Financial barriers may discourage some patients with from participating in cancer clinical trials. This study sought to assess the effect of an equity intervention on the financial burden of clinical trial participants.
Background. The financial
Background. The financial
Autor:
Morgan RL Lichtenstein, Khilna Patel, Peter Campbell, Michelle K. Nguyen, Erik Harden, John Spivack, Nicole Collins, Khadija Faheem, Melissa Parsons Beauchemin, Katherine D. Crew, Melissa Kate Accordino, Meghna S. Trivedi, Elena B. Elkin, Dawn L. Hershman
Publikováno v:
Journal of Clinical Oncology. 40:1592-1592
1592 Background: The past decade has seen a dramatic increase in the number of oral anti-cancer drug (OACD) approvals in the United States. Though polypharmacy and drug-drug interactions (DDIs) likely contribute to OACD toxicity, the prevalence of th
Autor:
Areej El-Jawahri, Laura A. Petrillo, Justin F. Gainor, Sienna Durbin, Kerry L. Reynolds, Ryan D. Nipp, Joseph A. Greer, Morgan Rl Lichtenstein, Jennifer S. Temel
Publikováno v:
CancerReferences. 126(10)
BACKGROUND Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end-of-life care. METHODS This was a retros
Autor:
Rohit R. Raghunathan, Dawn L. Hershman, Elena B. Elkin, Morgan Rl Lichtenstein, Melissa Beauchemin, Jason D. Wright, Cynthia Law, Sahil D Doshi, Melissa Kate Accordino
Publikováno v:
Journal of Clinical Oncology. 39:6-6
6 Background: The past decade has seen a dramatic increase in the number of Food and Drug Administration approvals of oral anti-cancer drugs (OACDs). Most OACD prescriptions require coordination between payers and providers, which can delay drug rece
Autor:
Morgan Rl Lichtenstein, Elena B. Elkin, Melissa Beauchemin, Cynthia Law, Jason D. Wright, Dawn L. Hershman, Rohit R. Raghunathan, Melissa Kate Accordino, Sahil D Doshi
Publikováno v:
Journal of Clinical Oncology. 39:41-41
41 Background: Oral anti-cancer drugs (OACDs) have become increasingly prescribed over the last 10 years and require a significant amount of care coordination. Preliminary administrative database studies have shown that 10-15% of prescriptions are ne
Autor:
Cynthia Law, Morgan Rl Lichtenstein, Melissa Beauchemin, Elena B. Elkin, Rohit R. Raghunathan, Jason D. Wright, Dawn L. Hershman, Melissa Kate Accordino, Sahil D Doshi
Publikováno v:
Journal of Clinical Oncology. 39:43-43
43 Background: Most oral anti-cancer drugs (OACD) prescriptions require extensive coordination between providers and payers, which can delay drug receipt. Specialty pharmacies are intended to facilitate communication between multiple entities to deli
Autor:
Morgan Rl Lichtenstein, Ryan D. Nipp, Joseph A. Greer, Laura A. Petrillo, Justin F. Gainor, Jennifer S. Temel, Kerry L. Reynolds, Areej El-Jawahri
Publikováno v:
Journal of Clinical Oncology. 37:49-49
49 Background: Immune checkpoint inhibitors (ICI) improve survival for adults with metastatic NSCLC. Despite limited data on ICI efficacy in adults with poor performance status (PS), oncologists often elect to treat this population with ICI given the
Autor:
Ryan D. Nipp, Morgan Rl Lichtenstein, Kelly Goodwin, Danyon Anderson, Justin F. Gainor, Richard Newcomb
Publikováno v:
Journal of Clinical Oncology. 36:10040-10040
10040Background: As the population ages, it has become increasingly important to understand the risks and benefits of novel agents among older adults with cancer. Immunotherapy (IO) has revolutioni...